Ticagrelor induced systemic inflammatory response syndrome.
BMC Cardiovasc Disord
; 17(1): 14, 2017 01 06.
Article
em En
| MEDLINE
| ID: mdl-28056791
ABSTRACT
BACKGROUND:
Ticagrelor is a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12. Possible adenosine-mediated effects of ticagrelor on inflammation are complex and incompletely understood. To our knowledge, ticagrelor-induced systemic inflammatory response syndrome (SIRS) has not yet been described. CASE PRESENTATION We report the case of an 84 years old patient presenting with SIRS subsequent to initiation of ticagrelor after implantation of two drug eluting stents. A broad diagnostic work-up for alternative causes and therapeutic measures were unrevealing. Discontinuation of the agent was followed by rapid improvement in clinical and laboratory signs of SIRS.CONCLUSIONS:
After exclusion of other causes, ticagrelor needs to be considered as a possible causative agent for SIRS. Due to the widespread use of ticagrelor, clinicians should be aware of this possible adverse drug reaction.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Adenosina
/
Síndrome de Resposta Inflamatória Sistêmica
/
Síndrome Coronariana Aguda
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Aged80
/
Humans
/
Male
Idioma:
En
Revista:
BMC Cardiovasc Disord
Assunto da revista:
ANGIOLOGIA
/
CARDIOLOGIA
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Suíça